BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang W, Tsuchiya K, Kurosaki M, Yasui Y, Inada K, Kirino S, Yamashita K, Sekiguchi S, Hayakawa Y, Osawa L, Okada M, Higuchi M, Takaura K, Maeyashiki C, Kaneko S, Tamaki N, Nakanishi H, Itakura J, Takahashi Y, Asahina Y, Enomoto N, Izumi N. Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. Cancers (Basel) 2019;11:E1517. [PMID: 31601010 DOI: 10.3390/cancers11101517] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Suzuki R, Goto R, Kawamura N, Watanabe M, Ganchiku Y, Hatanaka KC, Hatanaka Y, Kamiyama T, Shimamura T, Taketomi A. Efficient multiple treatments including molecular targeting agents in a case of recurrent hepatocellular carcinoma, post-living donor liver transplantation. Clin J Gastroenterol. [DOI: 10.1007/s12328-022-01643-3] [Reference Citation Analysis]
2 Eso Y, Nakano S, Mishima M, Arasawa S, Iguchi E, Nakamura F, Takeda H, Takai A, Takahashi K, Taura K, Seno H. Dose Intensity/Body Surface Area Ratio is a Novel Marker Useful for Predicting Response to Lenvatinib against Hepatocellular Carcinoma. Cancers (Basel). 2019;12:49. [PMID: 31877859 DOI: 10.3390/cancers12010049] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
3 Kim HD, Bang Y, Lee MA, Kim JW, Kim JH, Chon HJ, Kang B, Kang MJ, Kim I, Cheon J, Hwang JE, Kang JH, Byeon S, Hong JY, Ryoo BY, Lim HY, Yoo C. Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. Liver Int. 2020;40:2544-2552. [PMID: 32563213 DOI: 10.1111/liv.14573] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
4 Koroki K, Kanogawa N, Maruta S, Ogasawara S, Iino Y, Obu M, Okubo T, Itokawa N, Maeda T, Inoue M, Haga Y, Seki A, Okabe S, Koma Y, Azemoto R, Atsukawa M, Itobayashi E, Ito K, Sugiura N, Mizumoto H, Unozawa H, Iwanaga T, Sakuma T, Fujita N, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Saito T, Kondo T, Suzuki E, Ooka Y, Nakamoto S, Tawada A, Chiba T, Arai M, Kanda T, Maruyama H, Kato J, Kato N. Posttreatment after Lenvatinib in Patients with Advanced Hepatocellular Carcinoma. Liver Cancer 2021;10:473-84. [PMID: 34721509 DOI: 10.1159/000515552] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Hata K, Suetsugu K, Egashira N, Makihara Y, Itoh S, Yoshizumi T, Tanaka M, Kohjima M, Watanabe H, Masuda S, Ieiri I. Association of lenvatinib plasma concentration with clinical efficacy and adverse events in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol 2020;86:803-13. [PMID: 33095285 DOI: 10.1007/s00280-020-04178-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
6 Lee I, Chao Y, Lee P, Chen S, Chi C, Wu C, Wu K, Hou M, Huang Y. Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma. Cancers 2022;14:2014. [DOI: 10.3390/cancers14082014] [Reference Citation Analysis]
7 Kirstein MM, Scheiner B, Marwede T, Wolf C, Voigtländer T, Semmler G, Wacker F, Manns MP, Hinrichs JB, Pinter M, Vogel A. Sequential systemic treatment in patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2020;52:205-12. [PMID: 32432799 DOI: 10.1111/apt.15789] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
8 Eso Y, Nakano S, Mishima M, Arasawa S, Iguchi E, Takeda H, Takai A, Takahashi K, Seno H. Branched‐chain amino acid to tyrosine ratio is an essential pre‐treatment factor for maintaining sufficient treatment intensity of lenvatinib in patients with hepatocellular carcinoma. J Hepatobiliary Pancreat Sci 2020;27:913-21. [DOI: 10.1002/jhbp.821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Wang HW, Chuang PH, Su WP, Kao JT, Hsu WF, Lin CC, Huang GT, Lin JT, Lai HC, Peng CY. On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3758. [PMID: 34359658 DOI: 10.3390/cancers13153758] [Reference Citation Analysis]
10 Granito A, Marinelli S, Forgione A, Renzulli M, Benevento F, Piscaglia F, Tovoli F. Regorafenib Combined with Other Systemic Therapies: Exploring Promising Therapeutic Combinations in HCC. J Hepatocell Carcinoma 2021;8:477-92. [PMID: 34079777 DOI: 10.2147/JHC.S251729] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
11 Granito A, Forgione A, Marinelli S, Renzulli M, Ielasi L, Sansone V, Benevento F, Piscaglia F, Tovoli F. Experience with regorafenib in the treatment of hepatocellular carcinoma. Therap Adv Gastroenterol 2021;14:17562848211016959. [PMID: 34104211 DOI: 10.1177/17562848211016959] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 29.0] [Reference Citation Analysis]
12 Hiraoka A, Kumada T, Hatanaka T, Tada T, Kariyama K, Tani J, Fukunishi S, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Kawata K, Yasuda S, Toyoda H, Chikara O, Tamai T, Kakizaki S, Tojima H, Nagashima T, Ueno T, Takizawa D, Naganuma A, Ohama H, Nouso K, Tsutsui A, Nagano T, Itokawa N, Okubo T, Arai T, Imai M, Koizumi Y, Nakamura S, Joko K, Michitaka K, Hiasa Y, Kudo M; Real-life Practice Experts for HCC (RELPEC) Study Group, HCC 48 Group (hepatocellular carcinoma experts from 48 clinics in Japan), and GLSG (Gunma Liver Study Group). Therapeutic efficacy of lenvatinib as third-line treatment after regorafenib for unresectable hepatocellular carcinoma progression. Hepatol Res 2021;51:880-9. [PMID: 33837620 DOI: 10.1111/hepr.13644] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
13 Kudo M. Recent Advances in Systemic Therapy for Hepatocellular Carcinoma in an Aging Society: 2020 Update. Liver Cancer 2020;9:640-62. [PMID: 33442538 DOI: 10.1159/000511001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 10.5] [Reference Citation Analysis]
14 Ono A, Aikata H, Yamauchi M, Kodama K, Ohishi W, Kishi T, Ohya K, Teraoka Y, Osawa M, Fujino H, Nakahara T, Murakami E, Miki D, Kawaoka T, Abe-Chayama H, Zhang P, Liu S, Makokha GN, Tsuge M, Imamura M, Hayes CN, Chayama K. Circulating cytokines and angiogenic factors based signature associated with the relative dose intensity during treatment in patients with advanced hepatocellular carcinoma receiving lenvatinib. Ther Adv Med Oncol 2020;12:1758835920922051. [PMID: 32547646 DOI: 10.1177/1758835920922051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
15 Yamaoka K, Kawaoka T, Aikata H, Ando Y, Kosaka Y, Suehiro Y, Fujii Y, Uchikawa S, Morio K, Fujino H, Nakahara T, Murakami E, Yamauchi M, Tsuge M, Hiramatsu A, Imamura M, Takahashi S, Saeki Y, Kuroda S, Kobayashi T, Ohdan H, Miyata Y, Okada M, Chayama K. Complete Response for Advanced Hepatocellular Carcinoma by Conversion Surgery Therapy Following a Good Response of Regorafenib Despite Rapid Progressive Disease with Sorafenib. Intern Med 2021;60:2047-53. [PMID: 34193774 DOI: 10.2169/internalmedicine.5870-20] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Kudo M. Impact of Multi-Drug Sequential Therapy on Survival in Patients with Unresectable Hepatocellular Carcinoma. Liver Cancer 2021;10:1-9. [PMID: 33708635 DOI: 10.1159/000514194] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Sasaki R, Fukushima M, Haraguchi M, Miuma S, Miyaaki H, Hidaka M, Eguchi S, Matsuo S, Tajima K, Matsuzaki T, Hashimoto S, Ooba K, Kugiyama Y, Yatsuhashi H, Motoyoshi Y, Shigeno M, Kinoshita N, Nakao K. Response to Lenvatinib Is Associated with Optimal RelativeDose Intensity in Hepatocellular Carcinoma: Experience in Clinical Settings. Cancers (Basel). 2019;11:1769. [PMID: 31717674 DOI: 10.3390/cancers11111769] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
18 Facciorusso A, Abd El Aziz MA, Sacco R. Efficacy of Regorafenib in Hepatocellular Carcinoma Patients: A Systematic Review and Meta-Analysis. Cancers (Basel). 2019;12. [PMID: 31877664 DOI: 10.3390/cancers12010036] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]